minocycline hydrochloride · Journey · NDA 212379
Amzeeq
Earliest generic entry, as listed
8 Sep 2037
Blocked by patent: US 10398641, US 10849847. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 12 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10398641 | use U-2647 | 8 Sep 2037 |
| US 10849847 | use U-2647 | 8 Sep 2037 |
| US 10086080 | use U-2647 | 1 Oct 2030 |
| US 10137200 | use U-2647 | 1 Oct 2030 |
| US 10213512 | product, use U-2647 | 1 Oct 2030 |
| US 10265404 | product | 1 Oct 2030 |
| US 10517882 | use U-2647 | 1 Oct 2030 |
| US 10821187 | use U-2647 | 1 Oct 2030 |
| US 8865139 | product, use U-2647 | 1 Oct 2030 |
| US 8945516 | product | 1 Oct 2030 |
| US 8992896 | product, use U-2647 | 1 Oct 2030 |
| US 9675700 | product, use U-2647 | 1 Oct 2030 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 212379 · 001 · RLD | aerosol, foam, topical | EQ 4% BASE | 8 Sep 2037 |